GSK’s Ojjaara Scores Myelofibrosis Nod After Round-The-World Journey
The US FDA approved the JAK inhibitor momelotinib for myelofibrosis with anemia, with an analyst forecasting peak sales of more than $425m.
You may also be interested in...
The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.
The European Medicines Agency has OKd nine new medicines for EU-wide approval, but recommended against renewing the conditional marketing authorization of two drugs.
GSK remains confident of approval despite the delay, with hopes of blockbuster sales for its myelofibrosis candidate.